HealingWell
Search Close Search
☰

Head-to-head study entyvio vs xeljanz

Support Forums
>
Ulcerative Colitis
✚ New Topic ✚ Reply
❬ ❬ Previous Thread |Next Thread ❭ ❭
Posted 8/11/2022 7:13 AM (GMT -5)
Suggests xeljanz is more effective, in patients who have previously tried anti-tnf therapy.
https://www.sciencedirect.com/science/article/pii/s1542356522005109
Posted 8/11/2022 10:21 AM (GMT -5)
I wish I wouldn't have even wasted my time on Entyvio (or Stelara or Humira, for that matter), and just went right to Xeljanz.
Posted 8/11/2022 12:05 PM (GMT -5)
Interesting...thanks for posting....note that this was a low sample size and only moderately statistically powered study....only at 80%....id be careful about taking too many general statistical conclusions from this study
Posted 8/11/2022 1:01 PM (GMT -5)
Sure.... There are not many head-to-head studies for UC treatments unfortunately.
Posted 8/11/2022 2:42 PM (GMT -5)
its really strange why this is not done....the first was a large study on Vedo v Humira and Vedo won out but only on the TNF naive population....it seems to be that the drug companies are coy about putting their drugs up for 1-1 statistical analysis because of the effect on profits....and researchers are slow to create such studies due to the funding that they receive from drug companies....so its actually pretty hard to get 1-1 analyses in a double blind placebo controlled trial

the concept of statistical power will create significant type 1 errors even with sample sizes of 100....which underlines even more why we should be slow to believe ancedotal evidence based on 'it worked for me, it must therefore work for u' scenarios
Posted 8/11/2022 5:24 PM (GMT -5)
From the drug companies' perspective there is no incentive to do a head-to-head trial because they won't want to demonstrate their drug is less effective than a rival.... From the hospital side, I suppose they need to make a coordinated effort across borders and institutions in order to pool a large enough population. The study linked here has small numbers because the dutch population is small. Added to that, there has only been a need for such studies in the last 5 years or so, when the treatment options have expanded beyond tnf-inhibitors. I think more head to head studies will come but academic research moves sooo slowly.
Posted 8/11/2022 9:51 PM (GMT -5)
Interesting
✚ New Topic ✚ Reply